Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MVCD1
MCID: MCR129
MIFTS: 68

Microvascular Complications of Diabetes 1 (MVCD1)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Microvascular Complications of Diabetes 1

About this section

MalaCards integrated aliases for Microvascular Complications of Diabetes 1:

Name: Microvascular Complications of Diabetes 1 57 72 29 13 6 39
Proliferative Diabetic Retinopathy 12 72 54 15 17 70
Nonproliferative Retinopathy, Diabetic, Susceptibility to 57 6
Proliferative Retinopathy, Diabetic, Susceptibility to 57 6
Non-Proliferative Diabetic Retinopathy 72 17
Diabetic Nephropathy 72 70
Mvcd1 57 72
Microvascular Complications of Diabetes, Susceptibility to, 1 57
Nonproliferative Retinopathy, Diabetic 57
Nonproliferative Diabetic Retinopathy 70
Proliferative Retinopathy, Diabetic 57
Complications of Diabetes Mellitus 70
Diabetic End-Stage Renal Disease 72
Diabetes Complications 44
Diabetic Neuropathies 70
Diabetic Neuropathy 72
Pdr 12

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Cardiovascular diseases Neuronal diseases Nephrological diseases Eye diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:13207
OMIM® 57 603933
OMIM Phenotypic Series 57 PS603933
ICD9CM 34 362.02
MeSH 44 D048909
NCIt 50 C84457
SNOMED-CT 67 154679002
UMLS 70 C0004606 C0011881 C0011882 more
Sources

Summaries for Microvascular Complications of Diabetes 1

About this section
UniProtKB/Swiss-Prot : 72 Microvascular complications of diabetes 1: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 1, also known as proliferative diabetic retinopathy, is related to background diabetic retinopathy and microvascular complications of diabetes 7, and has symptoms including sciatica and neuralgia. An important gene associated with Microvascular Complications of Diabetes 1 is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Clopidogrel and Glimepiride have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and retina, and related phenotypes are cardiovascular system and cellular

Wikipedia : 73 Complications of diabetes mellitus include problems that develop rapidly (acute) or over time (chronic)... more...

More information from OMIM: 603933 PS603933
Sources

Related Diseases for Microvascular Complications of Diabetes 1

About this section

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 908)
# Related Disease Score Top Affiliating Genes
1 background diabetic retinopathy 33.2 VEGFA ICAM1 ANGPT2
2 microvascular complications of diabetes 7 33.0 HFE-AS1 HFE
3 severe nonproliferative diabetic retinopathy 32.9 VEGFA ICAM1 CXCL8 CCL2
4 renal fibrosis 32.2 MMP9 HGF CCN2 CCL2
5 macular holes 32.1 VEGFA SERPINF1 CXCL8 CCL2 ANGPT2
6 glomerulonephritis 31.9 VCAM1 ICAM1 CCN2 CCL2
7 cataract 31.5 VEGFA SERPINF1 IGF1 ICAM1 FGF2 CXCL8
8 endophthalmitis 31.5 VEGFA ICAM1 FLT1 CXCL8
9 type 1 diabetes mellitus 31.5 VEGFA SST IGF1 ICAM1 CXCL8 CCL2
10 preretinal fibrosis 31.4 VEGFA GFAP ANGPT2
11 uveitis 31.4 SERPINF1 ICAM1 CXCL8 CCL2
12 nephrosclerosis 31.4 VEGFA CCN2 CCL2
13 retinal vein occlusion 31.2 VEGFA SERPINF1 CXCL8 CXCL12 CCL2 ANGPT2
14 proteasome-associated autoinflammatory syndrome 1 31.2 VCAM1 MMP9 ICAM1 CXCL8 CCL2
15 retinal vascular disease 31.1 VEGFA SERPINF1 IGF1 ICAM1 FLT1 FGF2
16 carpal tunnel syndrome 31.1 VEGFA CCN2 CCL2
17 hypertension, essential 31.0 VEGFA VCAM1 SST MMP9 IGF1 ICAM1
18 pyelonephritis 31.0 MMP9 CXCL8 CCL2
19 arteries, anomalies of 31.0 VEGFA VCAM1 ICAM1 CCL2
20 malaria 31.0 VEGFA VCAM1 MMP9 ICAM1 FLT1 EPO
21 kidney disease 31.0 VEGFA VCAM1 HGF FLT1 EPO CCN2
22 crescentic glomerulonephritis 30.9 VCAM1 ICAM1 CCN2 CCL2
23 neuritis 30.9 VEGFA VCAM1 MMP9 HFE GFAP CXCL8
24 fibromyalgia 30.9 IGF1 CXCL8 CCL2
25 microvascular complications of diabetes 5 30.9 VEGFA VCAM1 SERPINF1 IGF1 ICAM1 FLT1
26 carotid stenosis 30.8 VEGFA VCAM1 MMP9 ICAM1 CXCL8
27 myopia 30.8 VEGFA SERPINF1 IGF1 HGF FGF2
28 transferrin serum level quantitative trait locus 2 30.8 HFE-AS1 HFE
29 ischemia 30.8 VEGFA ICAM1 HGF GFAP FLT1 FGF2
30 peripheral artery disease 30.7 VEGFA VCAM1 ICAM1 HGF FGF2 CCL2
31 lipoprotein quantitative trait locus 30.7 VEGFA VCAM1 MMP9 ICAM1 FGF2 CXCL8
32 tuberous sclerosis 30.7 VEGFA SST IGF1 GFAP
33 arteriosclerosis obliterans 30.7 VCAM1 ICAM1 HGF
34 hemoglobinopathy 30.7 VEGFA VCAM1 HFE EPO
35 chronic kidney disease 30.7 VEGFA VCAM1 MMP9 IGF1 ICAM1 HGF
36 vascular cancer 30.7 VEGFA FLT1 FGF2
37 vascular disease 30.7 VEGFA VCAM1 MMP9 IGF1 ICAM1 FGF2
38 diabetic neuropathy 30.7 VEGFA ICAM1 FGF2 EPO
39 peripheral vascular disease 30.7 VEGFA VCAM1 EPO CCL2
40 retinal artery occlusion 30.7 VEGFA FLT1 CXCL8 CCL2
41 pulmonary disease, chronic obstructive 30.7 MMP9 CXCL8 CCN2 CCL2
42 placenta disease 30.7 VEGFA FLT1 CXCL8
43 leukostasis 30.7 VEGFA VCAM1 SERPINF1 ICAM1 CCL2
44 end stage renal disease 30.6 VEGFA ICAM1 HFE EPO CCL2
45 intermittent claudication 30.6 VEGFA IGF1 ANGPT2
46 hemangioma 30.6 VEGFA MMP9 FLT1 FGF2 ANGPT2
47 severe pre-eclampsia 30.6 VEGFA VCAM1 MMP9
48 sleep apnea 30.6 VEGFA VCAM1 IGF1 ICAM1 EPO CXCL8
49 keratitis, hereditary 30.6 VEGFA MMP9 FLT1 FGF2 CXCL8
50 polycystic kidney disease 30.6 VEGFA VCAM1 SST MMP9 IGF1 FGF2

Comorbidity relations with Microvascular Complications of Diabetes 1 via Phenotypic Disease Network (PDN): (show all 22)


Acute Cystitis Acute Kidney Failure
Benign Essential Hypertension Chronic Kidney Disease
Decubitus Ulcer Deficiency Anemia
Diabetic Cataract Diabetic Polyneuropathy
Heart Disease Hypertension, Essential
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Kidney Disease
Microvascular Complications of Diabetes 7 Mitral Valve Disease
Neurogenic Arthropathy Peripheral Vascular Disease
Rubeosis Iridis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 1:



Diseases related to Microvascular Complications of Diabetes 1
Sources

Symptoms & Phenotypes for Microvascular Complications of Diabetes 1

About this section

Clinical features from OMIM®:

603933 (Updated 05-Apr-2021)

UMLS symptoms related to Microvascular Complications of Diabetes 1:


sciatica; neuralgia

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 1:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.36 ANGPT2 CCN2 CXCL12 EPO FGF2 FLT1
2 cellular MP:0005384 10.34 ANGPT2 CCN2 CXCL12 EPO FGF2 FLT1
3 homeostasis/metabolism MP:0005376 10.28 ANGPT2 CCN2 EPO FGF2 FLT1 GFAP
4 hematopoietic system MP:0005397 10.27 ANGPT2 CXCL12 EPO FGF2 FLT1 HFE
5 mortality/aging MP:0010768 10.27 ANGPT2 CCN2 CXCL12 EPO FGF2 FLT1
6 immune system MP:0005387 10.25 ANGPT2 CCL2 CXCL12 EPO FLT1 GFAP
7 digestive/alimentary MP:0005381 10.13 ANGPT2 CCN2 GFAP HFE ICAM1 MMP9
8 nervous system MP:0003631 10.03 CXCL12 FGF2 FLT1 GFAP HFE HGF
9 muscle MP:0005369 9.97 CXCL12 EPO FGF2 FLT1 GFAP ICAM1
10 normal MP:0002873 9.81 CCN2 CXCL12 EPO FLT1 GFAP HFE
11 skeleton MP:0005390 9.65 CCN2 EPO FGF2 HFE HGF IGF1
12 vision/eye MP:0005391 9.32 ANGPT2 CCN2 FGF2 FLT1 GFAP ICAM1
Sources

Drugs & Therapeutics for Microvascular Complications of Diabetes 1

About this section

Drugs for Microvascular Complications of Diabetes 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 475)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
2
Glimepiride Approved Phase 4 93479-97-1 3476
3
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
4
Canagliflozin Approved Phase 4 842133-18-0
5
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
6
Alogliptin Approved Phase 4 850649-61-5 11450633
7
Bevacizumab Approved, Investigational Phase 4 216974-75-3
8
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
9
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
10
Clonidine Approved Phase 4 4205-90-7 2803
11
Saxagliptin Approved Phase 4 361442-04-8 11243969
12
Insulin lispro Approved Phase 4 133107-64-9
13
Atorvastatin Approved Phase 4 134523-00-5 60823
14
Enalaprilat Approved Phase 4 76420-72-9 6917719
15
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
16
Doxazosin Approved Phase 4 74191-85-8 3157
17
Simvastatin Approved Phase 4 79902-63-9 54454
18
Sodium citrate Approved, Investigational Phase 4 68-04-2
19
Ramipril Approved Phase 4 87333-19-5 5362129
20
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
21
Acetaminophen Approved Phase 4 103-90-2 1983
22
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
23
Amitriptyline Approved Phase 4 50-48-6 2160
24
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
25 Grape Approved Phase 4
26
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
27
Dipivefrin Approved Phase 4 52365-63-6 3105
28
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
29
Insulin glulisine Approved Phase 4 207748-29-6
30
carbamide peroxide Approved Phase 4 124-43-6
31
Probucol Approved, Investigational Phase 4 23288-49-5 4912
32
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
33
Nisoldipine Approved Phase 4 63675-72-9 4499
34
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
35
Indapamide Approved Phase 4 26807-65-8 3702
36
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
37
Amlodipine Approved Phase 4 88150-42-9 2162
38
Atenolol Approved Phase 4 29122-68-7 2249
39
Cetirizine Approved Phase 4 83881-51-0 2678
40
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
41
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
42
Trandolapril Approved Phase 4 87679-37-6 5484727
43
Verapamil Approved Phase 4 52-53-9 2520
44
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
45
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
46
Captopril Approved Phase 4 62571-86-2 44093
47
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
48
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
49
Niclosamide Approved, Investigational, Vet_approved Phase 4 50-65-7 4477
50
tannic acid Approved Phase 4 1401-55-4

Interventional clinical trials:

(show top 50) (show all 991)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
2 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
3 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
4 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
5 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
6 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
7 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
8 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
9 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
10 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
11 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
12 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
13 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
14 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
15 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
16 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
17 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
18 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
19 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
20 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
21 The Effects of Empagliflozin on Functional and Structural Arterial Wall Characteristics Unknown status NCT03639545 Phase 4 Empagliflozin 25mg;Metformin;Empagliflozin/Metformin;Placebos
22 Effects of the DPP-4 or SGLT2 Inhibitors on the Metabolic Cardiovascular Systems in Patients With Type 2 Diabetes Mellitus. Unknown status NCT02528019 Phase 4 DPP-4 inhibiotors;SGLT2 inhibitors;Glimepiride
23 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
24 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
25 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
26 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
27 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
28 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide
29 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Completed NCT03271151 Phase 4 Cymbalta
30 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
31 A Multicenter Trial Evaluating the Efficacy of Cesametâ„¢ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesametâ„¢ (nabilone)
32 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
33 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
34 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
35 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
36 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
37 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
38 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
39 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
40 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
41 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
42 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
43 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapyâ„¢ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
44 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
45 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
46 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
47 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
48 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
49 Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area Completed NCT02834663 Phase 4 Lucentis
50 A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy Completed NCT03962296 Phase 4 Vitis vinifera extract;Calcium Dobesilate;Placebo

Search NIH Clinical Center for Microvascular Complications of Diabetes 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Becaplermin
benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
Captopril
Citalopram
Citalopram hydrobromide
COBALAMIN CONCENTRATE
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
irbesartan
Lisinopril
Losartan
Losartan Potassium
mecobalamin
Mexiletine
Mexiletine Hydrochloride
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Pentoxifylline
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan
Vitamin B 12

Cochrane evidence based reviews: diabetes complications

Sources

Genetic Tests for Microvascular Complications of Diabetes 1

About this section

Genetic tests related to Microvascular Complications of Diabetes 1:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 1 29 VEGFA
Sources

Anatomical Context for Microvascular Complications of Diabetes 1

About this section

MalaCards organs/tissues related to Microvascular Complications of Diabetes 1:

40
Endothelial, Eye, Retina, Bone, Skin, Spinal Cord, Bone Marrow
Sources

Publications for Microvascular Complications of Diabetes 1

About this section

Articles related to Microvascular Complications of Diabetes 1:

(show top 50) (show all 4383)
# Title Authors PMID Year
1
A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. 57 6 61
11978667 2002
2
Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. 61 54 57
15767056 2005
3
SDF-1 is both necessary and sufficient to promote proliferative retinopathy. 57 61 54
15630447 2005
4
Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. 61 57 54
12208249 2002
5
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. 6 61
18458324 2008
6
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. 57 61
17259996 2007
7
A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. 61 6
14618419 2003
8
Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. 57
20522428 2010
9
Genetic analysis of diabetic nephropathy on chromosome 18 in African Americans: linkage analysis and dense SNP mapping. 57
19690890 2009
10
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. 57
19881493 2009
11
Association of genetic variants at 3q22 with nephropathy in patients with type 1 diabetes mellitus. 57
19084216 2009
12
Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. 6
19084217 2009
13
Sequence variants in the PLEKHH2 region are associated with diabetic nephropathy in the GoKinD study population. 57
18752002 2008
14
High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach. 57
18559660 2008
15
Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. 6
18566337 2008
16
Iron-overload-related disease in HFE hereditary hemochromatosis. 6
18499578 2008
17
Iron-overload-related disease in HFE hereditary hemochromatosis. 6
18504828 2008
18
Association of CC chemokine ligand 5 genotype with urinary albumin excretion in the non-diabetic Japanese general population: the Takahata study. 57
18217191 2008
19
Genetic factors in diabetic nephropathy. 57
17942768 2007
20
Promoter polymorphisms of the pigment epithelium-derived factor gene are associated with diabetic retinopathy. 57
17658465 2007
21
Frequency of the hemochromatosis gene mutations in the population of Serbia and Montenegro. 6
16879202 2006
22
Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T>C polymorphisms on the susceptibility to diabetic nephropathy. 57
16813599 2006
23
A genome-wide DNA microsatellite association screen to identify chromosomal regions harboring candidate genes in diabetic nephropathy. 57
16467450 2006
24
Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. 57
15793258 2005
25
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. 57
15599399 2004
26
A genome scan for diabetic nephropathy in African Americans. 57
15458446 2004
27
Association of porphyria cutanea tarda with hereditary hemochromatosis. 6
15280838 2004
28
The HFE gene is associated to an earlier age of onset and to the presence of diabetic nephropathy in diabetes mellitus type 2. 6
15347835 2004
29
Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. 6
15060098 2004
30
Hemochromatosis mutations in the general population: iron overload progression rate. 6
15070663 2004
31
The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading. 6
14729817 2004
32
Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. 6
14673107 2003
33
Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. 6
12915468 2003
34
RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. 57
12610055 2003
35
Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. 57
12480514 2003
36
Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. 57
12427143 2002
37
Hereditary haemochromatosis: only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload. 6
12436244 2002
38
The hemochromatosis protein HFE inhibits iron export from macrophages. 6
12429850 2002
39
Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. 57
12208245 2002
40
Clinical haemochromatosis in HFE mutation carriers. 6
12241803 2002
41
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 57
11918623 2002
42
Co-selection of the H63D mutation and the HLA-A29 allele: a new paradigm of linkage disequilibrium? 6
11904676 2002
43
Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. 6
11812557 2002
44
Identification of an endogenous RNA transcribed from the antisense strand of the HFE gene. 6
11532995 2001
45
Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. 6
11423500 2001
46
Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? 6
11358905 2001
47
Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. 57
10884438 2000
48
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. 57
10859350 2000
49
Transforming growth factor beta contributes to progressive diabetic nephropathy. 57
10884396 2000
50
Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. 6
10401000 1999
Sources

Variations for Microvascular Complications of Diabetes 1

About this section

ClinVar genetic disease variations for Microvascular Complications of Diabetes 1:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HFE-AS1 , HFE NM_139011.3(HFE):c.77-2168C>G SNV Pathogenic 10 rs1799945 GRCh37: 6:26091179-26091179
GRCh38: 6:26090951-26090951
2 EPO NM_000799.3(EPO):c.-1306C>A SNV risk factor 16602 rs1617640 GRCh37: 7:100317298-100317298
GRCh38: 7:100719675-100719675
3 POLR1C , VEGFA NM_001025366.3(VEGFA):c.-94C>G SNV risk factor 12223 rs2010963 GRCh37: 6:43738350-43738350
GRCh38: 6:43770613-43770613
4 HFE NM_000410.3(HFE):c.845G>A (p.Cys282Tyr) SNV risk factor 9 rs1800562 GRCh37: 6:26093141-26093141
GRCh38: 6:26092913-26092913
5 HFE-AS1 , HFE NM_139011.3(HFE):c.77-2168C>G SNV risk factor 10 rs1799945 GRCh37: 6:26091179-26091179
GRCh38: 6:26090951-26090951
6 HFE-AS1 , HFE NM_000410.3(HFE):c.193A>T (p.Ser65Cys) SNV Uncertain significance 11 rs1800730 GRCh37: 6:26091185-26091185
GRCh38: 6:26090957-26090957
Sources

Expression for Microvascular Complications of Diabetes 1

About this section
Search GEO for disease gene expression data for Microvascular Complications of Diabetes 1.
Sources

Pathways for Microvascular Complications of Diabetes 1

About this section

Pathways related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.85 VEGFA IGF1 HGF FLT1 FGF2 CXCL8
2
TGF-Beta Pathway 63
Show member pathways
 13.45 VEGFA IGF1 ICAM1 HGF FLT1 FGF2
3
Akt Signaling 63
Show member pathways
 13.42 IGF1 HGF FLT1 FGF2 CXCL8 CXCL12
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.39 VEGFA VCAM1 MMP9 ICAM1 HGF FGF2
5
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.3 VEGFA IGF1 HGF FLT1 FGF2 CXCL12
6
PAK Pathway 63
Show member pathways
 13.3 IGF1 HGF FLT1 FGF2 CXCL8 CXCL12
7
Phospholipase-C Pathway 63
Show member pathways
 13.08 IGF1 HGF FLT1 FGF2 CXCL12 CCN2
8
p70S6K Signaling 63
Show member pathways
 13.04 VCAM1 IGF1 HGF FLT1 FGF2 CXCL12
9
PI3K-Akt signaling pathway 36
Show member pathways
 13.01 VEGFA IGF1 HGF FLT1 FGF2 EPO
10
Human cytomegalovirus infection 36
Show member pathways
 12.95 VEGFA ICAM1 FGF2 CXCL8 CXCL12 CCL2
11
Pathways in cancer 36
12.8 VEGFA MMP9 IGF1 HGF FGF2 EPO
12
MAPK signaling pathway 36 1
12.79 VEGFA IGF1 HGF FLT1 FGF2 ANGPT2
13
Ras signaling pathway 36
Show member pathways
 12.76 VEGFA IGF1 HGF FLT1 FGF2 ANGPT2
14
NF-KappaB Family Pathway 63
Show member pathways
 12.73 IGF1 HGF FLT1 FGF2 CXCL12 CCN2
15
Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling Pathways 64
Show member pathways
 12.67 VEGFA VCAM1 MMP9 ICAM1 CXCL12 CCL2
16
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.44 IGF1 HGF FLT1 FGF2 CXCL12 CCN2
17
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.41 VEGFA VCAM1 ICAM1 CCL2
18
Calcium signaling pathway 36
12.4 VEGFA HGF FLT1 FGF2
19
Proteoglycans in cancer 36
12.34 VEGFA MMP9 IGF1 HGF FGF2
20
Transcriptional misregulation in cancer 36
12.29 MMP9 IGF1 FLT1 CXCL8
21
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.26 IGF1 HGF FLT1 FGF2 CXCL8 CXCL12
22
Fluid shear stress and atherosclerosis 36
12.12 VEGFA VCAM1 MMP9 ICAM1 CCL2
23
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.09 VEGFA VCAM1 IGF1 HGF FGF2
24
Adhesion 4
12.06 VCAM1 MMP9 ICAM1 CCN2
25
TNF signaling pathway 36
12.02 VCAM1 MMP9 ICAM1 CCL2
26
Spinal Cord Injury 1
12.02 MMP9 ICAM1 GFAP CXCL8 CCL2
27
NF-kappa B signaling pathway 36
11.98 VCAM1 ICAM1 CXCL8 CXCL12
28
HIF-1 signaling pathway 36
11.97 VEGFA IGF1 FLT1 EPO ANGPT2
29
AGE-RAGE signaling pathway in diabetic complications 36
11.92 VEGFA VCAM1 ICAM1 CXCL8 CCL2
30
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.82 VEGFA IGF1 GFAP FGF2
31
LT-BetaR Pathway 63
Show member pathways
 11.81 VCAM1 CXCL8 CXCL12
32
G-protein signaling_RhoA regulation pathway 23
11.78 IGF1 HGF FGF2 CXCL12 CCN2
33
Rheumatoid arthritis 36
11.77 VEGFA ICAM1 FLT1 CXCL8 CXCL12 CCL2
34
Bladder cancer 36 1
11.75 VEGFA MMP9 CXCL8
35
Endochondral Ossification 1
11.71 VEGFA MMP9 IGF1 FGF2
36
HIF-1-alpha transcription factor network 1
11.7 VEGFA EPO CXCL12
37
Angiogenesis (CST) 4
11.68 MMP9 HGF